XORTX Therapeutics Announces Effective Date for 1-for-5 Share Consolidation

XORTX Therapeutics Inc. announced the effective date for its previously disclosed share consolidation. Following the receipt of all necessary approvals from the TSX Venture Exchange and the Nasdaq Stock Exchange, the company will implement a 1-for-5 reverse stock split (the 'Consolidation'). The consolidation is scheduled to occur on April 6, 2026. Under the terms of the action, every five old common shares will be exchanged for one new common share. XORTX is a late-stage clinical pharmaceutical company focused on developing therapies for gout and progressive kidney disease, including its lead program XRx-026 for gout and XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD). The filing does not mention any updates regarding clinical trial timelines or upcoming data readouts.